ACORN CAPITAL ADVISORS, LLC

Est. AUM

$351.84B

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	TERNS PHARMACEUTICALS INC	COM	$92.06B	1746264	26.17%	SOLE
2	CG ONCOLOGY INC	COM	$76.58B	1130501	21.77%	SOLE
3	UROGEN PHARMA LTD	COM	$30.09B	1673420	8.55%	SOLE
4	PUMA BIOTECHNOLOGY INC	COM	$26.40B	4131299	7.50%	SOLE
5	TREVI THERAPEUTICS INC	COM	$25.59B	2144844	7.27%	SOLE
6	CANDEL THERAPEUTICS INC	COM	$17.21B	3497948	4.89%	SOLE
7	BICARA THERAPEUTICS	COM	$12.80B	643382	3.64%	SOLE
8	ONKURE THERAPEUTICS INC	CLASS A COM	$11.76B	2839674	3.34%	SOLE
9	JADE BIOSCEINCES INC	COM NEW	$11.05B	786760	3.14%	SOLE
10	PROTARA THERAPEUTICS INC	COM STK	$9.13B	1752115	2.59%	SOLE
11	VERASTEM INC	COM	$7.79B	1469153	2.21%	SOLE
12	HELUS PHARMA INC.	COM STK	$7.39B	1540266	2.10%	SOLE
13	LEONABIO, INC.	COMMON STOCK	$6.52B	634539	1.85%	SOLE
14	AURA BIOSCIENCES INC	COM	$3.99B	595744	1.13%	SOLE
15	WHITEHAWK THERAPEUTICS INC	COM	$3.93B	1139363	1.12%	SOLE
16	CARDIF ONCOLOGY INC	COM	$2.85B	1762084	0.81%	SOLE
17	Q32 BIO INC.	COM	$2.02B	315052	0.57%	SOLE
18	KARYOPHARM THERAPEUTICS INC	COMMON STOCK	$1.60B	287826	0.46%	SOLE
19	JASPER THERAPEUTICS	COM	$1.24B	1411492	0.35%	SOLE
20	X4 PHARMACEUTICALS INC	COM	$966.6M	234039	0.27%	SOLE
21	BIOATLA INC	COM	$865.0M	5406345	0.25%	SOLE
22	VYNE THERAPEUTICS INC	COM	$855K	1425	0.00%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.